This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (56)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MAJ Greta C. Zimmerman, MC; COL James H. Keeling, MC; MAJ Howard A. Burris, MC; Gayle Cook, RN; Rebecca Irvin, RPh; John Kuhn, RPh; LTC Martha L. McCollough, MC; Daniel D. Von Hoff, MD

Arch Dermatol. 1995;131(2):202-206.

Abstract
Background
Docetaxel (RP 56976) is a new chemotherapeutic agent that has shown promise in a number of animal studies and is currently undergoing phase I and phase II trials. Early in the phase I trials, it was noted that a significant number of patients were experiencing a variety of cutaneous complaints, so we elected to prospectively evaluate the cutaneous reactions occurring during the first three courses of therapy in the first 12 patients enrolled for phase I chemotherapy at our institutions.

Observations
All but one patient had some type of cutaneous eruption over the three courses of therapy. Of the 27 evaluable courses of docetaxel given, 19 (70%) resulted in a cutaneous eruption with four (21%) being asymptomatic and 15 (79%) being at least mildly symptomatic. The most common reaction seen was characterized by discrete erythematous to violaceous patches or edematous plaques similar to acral erythema.

Conclusion
Although a majority of patients receiving docetaxel experience some degree of cutaneous reaction, the eruptions are usually mildly symptomatic and almost always self-limiting.

(Arch Dermatol. 1995;131:202-206)

Author Affiliations
USA; USA; USA; USA

From the Departments of Medicine, Dermatology Service (Drs Zimmerman, Keeling, and McCollough), Hematology/Oncology Service (Dr Burris), Brooke Army Medical Center, Fort Sam Houston, Tex; and The University of Texas Health Science Center at San Antonio and The Cancer Therapy and Research Center, San Antonio (Mss Cook and Irvin, Mr Kuhn, and Dr Von Hoff).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cutaneous reaction associated with weekly docetaxel administration
Chew and Chuen
J Oncol Pharm Pract 2009;15:29-34.
ABSTRACT  

Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer
Schwartz et al.
Ann Oncol 2005;16:247-252.
ABSTRACT | FULL TEXT  

Palmar-plantar erythrodysesthesia
Gilbar
J Oncol Pharm Pract 2003;9:137-150.
ABSTRACT  

Cutaneous Reactions to Chemotherapy Drugs: The Art of Consultation
Remlinger
Arch Dermatol 2003;139:77-81.
FULL TEXT  

Phase I and Pharmacokinetic Study of Escalating Dose of Docetaxel Administered with Granulocyte Colony-stimulating Factor Support in Adult Advanced Solid Tumors
Goncalves et al.
Clin. Cancer Res. 2003;9:102-108.
ABSTRACT | FULL TEXT  

Phase I Trial of Docetaxel with Filgrastim Support in Pediatric Patients with Refractory Solid Tumors: A Collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group Trial
Seibel et al.
Clin. Cancer Res. 1999;5:733-737.
ABSTRACT | FULL TEXT  

Nail Bed Dyschromia Secondary to Docetaxel Therapy
Jacob and Frunza Patten
Arch Dermatol 1998;134:1167-1168.
FULL TEXT  

Allergic Reactions to Drugs and Biologic Agents
deShazo and Kemp
JAMA 1997;278:1895-1906.
ABSTRACT  

Cutaneous Side Effects of Docetaxel
Journal Watch Dermatology 1995;1995:11-11.
FULL TEXT